Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study
| Autor: | C Maulard-Durdux, Martin Housset, Christophe Hennequin, M E Toubert |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pathology Tissue Polypeptide Antigen Gastroenterology Internal medicine Biomarkers Tumor Carcinoma medicine Humans Prospective cohort study Aged Tumor marker Aged 80 and over Carcinoma Transitional Cell Bladder cancer Urinary bladder business.industry Radioimmunoassay Middle Aged medicine.disease Survival Analysis Transitional cell carcinoma medicine.anatomical_structure Urinary Bladder Neoplasms Oncology Evaluation Studies as Topic Female Reagent Kits Diagnostic business Follow-Up Studies |
| Zdroj: | Journal of Clinical Oncology. 15:3446-3450 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | PURPOSE Tissue polypeptide antigen (TPA) is a differentiation and proliferation tissue marker of epithelia. Increased serum levels were found in some patients with invasive bladder cancer. We present the results of a prospective study that evaluated the role of serum TPA (S-TPA) in bladder carcinoma. PATIENTS AND METHODS The series included 167 patients treated for invasive bladder cancer between 1989 and 1996. S-TPA concentrations were measured by radioimmunoassay before treatment, at the end of treatment, and during follow-up evaluation. The upper normal limit of the test was set at 80 UI/L. RESULTS With a specificity of 100%, the diagnostic sensitivity was 46%. Pretherapeutic S-TPA levels were significantly correlated with tumor stage (T2 v T3 and T4; P = .02), with nodal stage (N0 v N1 and N2; P = .00001), and with metastatic stage (M0 v M1; P = 10[-6]), but not with histologic grading (grade 1 and 2 v 3). In the subset of patients with normal pretherapeutic S-TPA levels, 95% had no residual disease at the end of treatment, compared with 53% of patients with initial elevated S-TPA (P = 10[-8]). Among patients who achieved a complete response, 27% experienced a relapse, with an increase of S-TPA in 72% of cases. The mean follow-up time was 20 +/- 17 months. For patients with normal pretherapeutic S-TPA levels, 3-year overall survival and disease-free survival rates were 76% and 67% respectively. These were 46% (P = .001) and 25% (P = 10[-7]), respectively, for patients with high pretherapeutic S-TPA. Multivariate analysis showed that S-TPA was an independent prognostic factor for survival (P = .03). CONCLUSION In invasive bladder cancer, S-TPA level is correlated with initial tumor stage. It is a valuable parameter for follow-up evaluation and appears to be a prognostic factor in multivariate analysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|